TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies.
TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.
For any media inquiry or investor relations, contact ir@tiumbio.com
Company Details
- Employees
- 13
- Founded
- -
- Address
- 6f, Pangyo It Center, 30 Changup-Ro 40 Beon-Gil, Sujeong-Gu, Seongnam-Si,gyeonggi-Do 13449,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.tiumbio.com/en/
- Keywords
- Rare diseases, Hemophilia, Immuno-oncology, Discovery, Development, Small molecules, Women's health, Endometiosis.
- HQ
- Seongnam-si, Gyeonggi-do
Tiumbio Questions
Tiumbio's website is http://www.tiumbio.com/en/
Tiumbio's LinkedIn profile is https://www.linkedin.com/company/tiumbio
Tiumbio has
13 employees.
View email and phone details for 13
employees at Tiumbio.
Tiumbio's industry is
Biotechnology Research
Tiumbio's top competitors are
Protium Science - Cdmo,
Stgen Bio,
Abion Inc.,
Idience,
Hk Inno-N,
Onconic Therapeutics,
Vari Bioscience Gmbh,
Viramal Limited,
Gi Innovation,
Gesynta Pharma Ab.
Tiumbio's categories are Biotechnology Research
Tiumbio's founding year is 2016
